Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efalizumab · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
Inclusion criteria: * Clinical diagnosis of moderate to severe rheumatoid arthritis. * On stable dose of methotrexate. * 18 to 80 years of age. * Less than 275 lbs. Exclusion criteria: * Joint replacement surgery within 60 days of the start of drug dosing. * Intra-articular cortisone injections w...
Top 20 of 31 competitors
Efalizumab is an investigational monoclonal antibody being studied for psoriatic arthritis and rheumatoid arthritis, both immune-mediated inflammatory conditions. It is in Phase 1 clinical development, and no regulatory approval for any indication has been established. XOMA Royalty Corporation is the developer.
Efalizumab targets ITGAL and ITGB2, which together form the integrin receptor LFA-1. By binding these targets, efalizumab acts as an inhibitor of LFA-1-mediated cellular adhesion and T-cell activation, a mechanism relevant to inflammatory joint diseases such as psoriatic arthritis and rheumatoid arthritis.
Efalizumab is being developed by XOMA Royalty Corporation, which trades under the ticker XOMA. The company is responsible for advancing the monoclonal antibody through clinical development for psoriatic arthritis and rheumatoid arthritis.
Efalizumab is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. The Phase 1 program has focused on safety, efficacy, and pharmacokinetics in patients with psoriatic arthritis.
Efalizumab has been evaluated in two completed clinical trials. NCT00051662 was a Phase 1 study of safety, efficacy, and pharmacokinetics in psoriatic arthritis, enrolling 45 patients. NCT00034203 was a Phase 2 study of safety and efficacy in rheumatoid arthritis conducted in the United States.
No. Efalizumab is an investigational monoclonal antibody in Phase 1 clinical development and has not been approved by the FDA for psoriatic arthritis, rheumatoid arthritis, or any other indication. It remains under study by XOMA Royalty Corporation.